Keyphrases
Adverse Effects
66%
Atezolizumab
16%
Cancer Diagnosis
16%
Cancer Immunotherapy
16%
Chemotherapy
50%
Clinical Outcomes
16%
Durvalumab
16%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
33%
Low Risk
16%
Lung Cancer Outcomes
100%
Nivolumab
16%
Non-small Cell Lung Cancer (NSCLC)
100%
Observational Data
16%
Overall Survival
16%
Overall Survival Progression-free Survival
16%
PD-L1 Expression
16%
Pembrolizumab
16%
Placebo
16%
Programmed Death-ligand 1 (PD-L1)
100%
Progression-free Survival
33%
Prospero
16%
Quality of Life
66%
Randomized Controlled Trial
50%
Risk of Death
16%
Search Results
16%
Treatment Outcome
16%
Treatment-related
33%
Trial Data
16%
Medicine and Dentistry
Adverse Effect
100%
Atezolizumab
25%
Cancer Diagnosis
25%
Cancer Immunotherapy
25%
Durvalumab
25%
Immunotherapy
100%
Nivolumab
25%
Non Small Cell Lung Cancer
100%
Observational Study
50%
Overall Survival
50%
Pembrolizumab
25%
Placebo
25%
Progression Free Survival
75%
Quality of Life
100%
Randomized Controlled Trial
75%
Systematic Review
100%
Pharmacology, Toxicology and Pharmaceutical Science
Atezolizumab
20%
Chemotherapy
60%
Durvalumab
20%
Immunotherapy
100%
Malignant Neoplasm
20%
Nivolumab
20%
Non Small Cell Lung Cancer
100%
Observational Study
40%
Overall Survival
40%
Pembrolizumab
20%
Placebo
20%
Progression Free Survival
60%
Randomized Controlled Trial
60%
Neuroscience
Adverse Effect
100%
Atezolizumab
25%
Cancer Immunotherapy
25%
Durvalumab
25%
Immunotherapy
100%
Lambrolizumab
25%
Nivolumab
25%
Placebo
25%
Randomized Controlled Trial
75%